METVIXIA Drug Patent Profile

Which patents cover Metvixia, and when can generic versions of Metvixia launch?

Metvixia is a drug marketed by Galderma Labs Lp and is included in one NDA.

The generic ingredient in METVIXIA is methyl aminolevulinate hydrochloride. There are four hundred and ninety-one drug master file entries for this compound. Additional details are available on the methyl aminolevulinate hydrochloride profile page.

Summary for METVIXIA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	4
Patent Applications:	45
DailyMed Link:	METVIXIA at DailyMed

Recent Clinical Trials for METVIXIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Institut de Cancérologie de Lorraine	Phase 2
Centre Hospitalier Universitaire de Nīmes	N/A
Galderma R&D	Phase 1

See all METVIXIA clinical trials

US Patents and Regulatory Information for METVIXIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	METVIXIA	methyl aminolevulinate hydrochloride	CREAM;TOPICAL	021415-001	Jul 27, 2004		DISCN	No	No

Expired US Patents for METVIXIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	METVIXIA	methyl aminolevulinate hydrochloride	CREAM;TOPICAL	021415-001	Jul 27, 2004

International Patents for METVIXIA

See the table below for patents covering METVIXIA around the world.

Country	Patent Number	Title	Estimated Expiration
China	1137087
Hungary	225148	ESTERS OF 5-AMINOLEVULINIC ACID AS PHOTOSENSITIZING AGENTS IN PHOTOCHEMOTHERAPY OR DIAGNOSIS, PRODUCTS AND KITS COMPRISING THEREOF AND METHOD OF IN VITRO DIAGNOSIS BY THEIR USING
European Patent Office	0820432	ESTERS DE L'ACIDE 5-AMINOLEVULINIQUE EN TANT QU'AGENTS PHOTOSENSIBILISANTS EN PHOTOCHIMIOTHERAPIE (ESTERS OF 5-AMINOLEVULINIC ACID AS PHOTOSENSITIZING AGENTS IN PHOTOCHEMOTHERAPY)
Norway	2005024
Norway	2005019

Supplementary Protection Certificates for METVIXIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2213652	SPC/GB15/010	United Kingdom		PRODUCT NAME: FLORBETABEN (18F), WHICH IS (4-((E)-2-(4-(2-(2-(2-(1F)FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHENYL)-N-METHYLANILINE); REGISTERED: UK EU/1/13/906/001 20140224
2826776	122021000025	Germany		PRODUCT NAME: EINE KOMBINATION VON (A) (R)-1-(2,2-DIFLUORBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANCARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND (B) N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1306 20181031
0252504	C960032	Netherlands		PRODUCT NAME: ACIDUM IBANDRONICUM, DESGEWENST IN DE VORM VAN EEN FARMACOLO- GISCH AANVAARDBAAR ZOUT OF IN DE VORM VAN EEN ESTER MET METHANOL,ETHANOL,2-PROPANOL OF 2-METHYLPROPANOL, OF IN DE VORM VEN EEN HYDRAAT,I.H.B.MONONATRIUM IBANDRONAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/96/012/001 19960625
2653873	301215	Netherlands		PRODUCT NAME: DIMETHYLFUMARAAT; REGISTRATION NO/DATE: EU/1/13/837 20140203
1532149	92128	Luxembourg		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE

METVIXIA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Oncology Drugs: A Focus on METVIXIA and the Broader Market

Introduction to Oncology Drugs Market

The global oncology drugs market is experiencing rapid growth, driven by increasing cancer prevalence, advancements in treatment options, and rising demand for innovative therapies. Here, we will delve into the market dynamics and financial trajectory of oncology drugs, with a specific focus on METVIXIA, although direct data on METVIXIA is limited, we will contextualize it within the broader oncology market.

Global Oncology Drugs Market Overview

The global oncology drugs market was valued at $231.56 billion in 2024 and is projected to reach $532.91 billion by 2031, growing at a CAGR of 12.6% during the forecast period[1].

Market Segmentation

• Drug Type: The market is segmented into various drug types, including cytotoxic drugs, targeted therapies, and immunotherapies. Cytotoxic drugs currently hold the largest market share, but targeted therapies are expected to emerge as the dominant segment by 2031 due to their higher efficacy and reduced side effects[1].
• Therapy: Chemotherapy is the current leading therapy segment, but targeted therapy and immunotherapy are gaining traction with significant CAGRs[1].
• Cancer Type: Lung cancer accounts for the maximum revenue generation due to its high prevalence and mortality rates globally[1].

Key Drivers and Restraints

• Drivers: The increasing prevalence of various cancers globally and the rising demand for innovative treatment options are key drivers. Advancements in targeted drug delivery systems and the adoption of targeted therapies and immunotherapies also fuel market growth[1].
• Restraints: High development costs and stringent government regulations are significant restraints in the market[1].

Geographical Analysis

• North America: Currently, North America holds the largest share in the oncology drugs market due to the availability of advanced treatment options and infrastructure. However, the Asia Pacific region is expected to witness the highest growth through 2031, driven by developing healthcare infrastructure, rising disposable incomes, and a growing patient population in countries like China and India[1].

Financial Performance and Projections

• The oncology drugs market is expected to see significant financial growth, with a projected CAGR of 12.6% from 2024 to 2031. This growth is underpinned by the increasing adoption of advanced therapies and the expanding patient population[1].

METVIXIA in the Context of Oncology Drugs

While specific financial data on METVIXIA is not provided, it can be understood within the broader context of the oncology drugs market.

• Innovative Therapies: METVIXIA, like other oncology drugs, benefits from the trend towards targeted and innovative therapies. These drugs have higher efficacy and reduced side effects, which are key factors driving market growth[1].
• Market Share: Although METVIXIA's specific market share is not detailed, it would likely fall under the targeted therapy segment, which is expected to grow significantly over the forecast period[1].

Competitive Landscape

The oncology drugs market is highly competitive, with key players such as Hoffmann-La Roche Ltd., Genentech, Inc., Novartis AG, Gilead Sciences Inc., AstraZeneca, and others. These companies are continuously investing in R&D to develop novel mechanisms and drugs, which is a critical factor in the market's growth[1].

Impact of Regulatory and Economic Factors

• Regulatory Environment: Stringent government regulations can impact the development and approval of oncology drugs. However, advancements in scientific knowledge and the focus on precision medicines are changing the regulatory landscape and economic implications of drug development[3].
• Economic Factors: The Inflation Reduction Act and other economic policies can influence the market by affecting pricing strategies and the development pipeline. Manufacturers are adjusting their portfolios and R&D strategies in response to these changes[4].

Patient Access and Market Trends

• Patient Access: The use of cash pay options, drug discount cards, and telehealth services is increasing, reflecting changes in patient access to care. This shift can impact traditional market models and pricing strategies[4].
• Biosimilar Adoption: The adoption of biosimilars is another trend, although their market share remains limited due to various channel tactics by innovators. This dynamic can influence the pricing and market share of branded oncology drugs[4].

Financial Trajectory for Oncology Drugs

The financial trajectory for oncology drugs is robust, with significant growth projected over the next several years. Here are some key financial highlights:

• Revenue Growth: The market is expected to grow from $231.56 billion in 2024 to $532.91 billion by 2031[1].
• CAGR: A CAGR of 12.6% is anticipated during the forecast period, driven by increasing demand and advancements in treatment options[1].
• Geographical Growth: Asia Pacific is expected to witness the highest growth, driven by developing healthcare infrastructure and rising patient populations[1].

Key Takeaways

• The global oncology drugs market is poised for significant growth driven by increasing cancer prevalence and advancements in treatment options.
• Targeted therapies and immunotherapies are expected to drive market growth, surpassing cytotoxic drugs by 2031.
• North America currently leads the market, but Asia Pacific is expected to show the highest growth.
• Regulatory and economic factors, including the Inflation Reduction Act, are influencing market dynamics.
• Patient access trends, such as the use of cash pay options and biosimilars, are changing traditional market models.

FAQs

Q: What is the projected growth rate of the global oncology drugs market from 2024 to 2031? A: The global oncology drugs market is expected to grow at a CAGR of 12.6% from 2024 to 2031[1].

Q: Which segment is expected to dominate the oncology drugs market by 2031? A: The targeted therapy segment is expected to emerge as the largest segment by 2031, driven by growing clinical evidence demonstrating the potential of targeted drugs[1].

Q: What are the key drivers of the oncology drugs market? A: Key drivers include the increasing prevalence of various cancers globally and the rising demand for innovative treatment options, as well as advancements in targeted drug delivery systems[1].

Q: How is the Asia Pacific region contributing to the growth of the oncology drugs market? A: The Asia Pacific region is expected to witness the highest growth, driven by developing healthcare infrastructure, rising disposable incomes, and a growing patient population in countries like China and India[1].

Q: What impact do regulatory and economic factors have on the oncology drugs market? A: Regulatory and economic factors, such as stringent government regulations and policies like the Inflation Reduction Act, influence the market by affecting pricing strategies and the development pipeline[3][4].

Cited Sources

1. Coherent Market Insights: "Oncology Drugs Market to Reach USD 532.91 Billion by 2031"[1]
2. Business Wire: "Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024"[2]
3. National Bureau of Economic Research: "The Economics of Drug Development: Pricing and Innovation in a Changing Market"[3]
4. IQVIA: "Top 10 U.S. Market Access Trends for 2024"[4]